09:57 AM EDT, 07/02/2024 (MT Newswires) -- Novavax ( NVAX ) said Tuesday that it has submitted an application with Health Canada for authorization of its 2024-2025 Formula Covid-19 vaccine for individuals 12 years and older.

The updated vaccine targets JN.1, KP.2, KP.3, and other JN.1 sublineage strains, Novavax ( NVAX ) Chief Executive Officer John C. Jacobs said.

The company said it aims to make the vaccine available in Canada immediately upon approval.

Price: 12.79, Change: +0.06, Percent Change: +0.46